A phase II trial to investigate the efficacy of AMX0035 in patients with mild cognitive impairment or mild-to-moderate Alzheimer's disease

Trial Profile

A phase II trial to investigate the efficacy of AMX0035 in patients with mild cognitive impairment or mild-to-moderate Alzheimer's disease

Planning
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Sodium phenylbutyrate/tauroursodeoxycholic acid (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Oct 2017 New trial record
    • 24 Oct 2017 This trial is expected to begin in the first half of 2018, according to an Alzheimer's Drug Discovery Foundation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top